42 filings
8-K
RAPT
RAPT Therapeutics Inc
7 Mar 24
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
8:03am
8-K
RAPT
RAPT Therapeutics Inc
22 Feb 24
Regulation FD Disclosure
5:13pm
8-K
RAPT
RAPT Therapeutics Inc
20 Feb 24
Other Events
4:29pm
8-K
RAPT
RAPT Therapeutics Inc
13 Nov 23
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
8:03am
8-K
RAPT
RAPT Therapeutics Inc
3 Nov 23
Regulation FD Disclosure
12:03pm
8-K
nffo4
11 Aug 23
Other Events
4:02pm
8-K
xa3h2j tbchnu8
11 Aug 23
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
8:05am
8-K
k737uto51c1rnnhb
26 May 23
Submission of Matters to a Vote of Security Holders
8:01am
8-K
mduk 4yr936e
11 May 23
RAPT Therapeutics Reports First Quarter 2023 Financial Results
8:10am
8-K
73seczx9kmp3n
14 Mar 23
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
8:05am
8-K
5lfk63uvn px01gmus7
10 Mar 23
Regulation FD Disclosure
4:52pm
8-K
qv686f6e
9 Jan 23
Other Events
8:01am
8-K
f28g0e
12 Dec 22
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy
4:03pm
8-K
2cl41lqy3t l18daw82
22 Nov 22
Other Events
4:09pm
8-K
am6dzhehs0sn 6bo
10 Nov 22
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
8:11am
8-K
p8trmegdcuaqoiea
6 Sep 22
Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation
4:21pm
8-K
k1deu7 o89l25kzr
11 Aug 22
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
8:10am
8-K
hfzoyjxu
31 May 22
RAPT Therapeutics Announces Private Placement Financing of $50 Million
4:18pm
8-K
ixeanrdpeb9r5
26 May 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
9eh92he9wm
23 May 22
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
8:16am